| 包装: | 1mg |
| 规格: | 98% |
| 市场价: | 5927元 |
| 分子量: | 703.1 |
Background:
C16 Glucosylceramide-d3is intended for use as an internal standard for the quantification of C16 glucosylceramide by GC- or LC-MS. C16 glucosylceramide is an endogenous bioactive sphingolipid.1,2It is a precursor in the synthesis of C16 lactosylceramide that is formedviametabolism of C16 ceramide by glucosylceramide synthase.3Inhalation of C16 glucosylceramide reduces lung colonization byP. aeruginosaand increases survival in a mouse model of cystic fibrosis.1C16 Glucosylceramide levels are elevated in the plasma of Parkinson's disease patients with cognitive impairments.2[Matreya, LLC. Catalog No. 1533]
1.Kovacic, B., Sehl, C., Wilker, B., et al.Glucosylceramide critically contributes to the host defense of cystic fibrosis lungsCell Physiol. Biochem.41(3)1208-1218(2017) 2.Mielke, M.M., Maetzler, W., Haughey, N.J., et al.Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: A pilot studyPLoS One8(9)e73094(2013) 3.Holland, W.L., and Summers, S.A.Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolismEndocr. Rev.29(4)381-402(2008)
m.cnreagent.com